Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fingolimod
Drug ID BADD_D02464
Description Multiple sclerosis or MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod is currently being studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Phase 2 clinical trials are currently underway and completion is expected in July 2020.[L12654]
Indications and Usage Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Marketing Status Not Available
ATC Code L04AA27
DrugBank ID DB08868
KEGG ID D10001
MeSH ID D000068876
PubChem ID 107970
TTD Drug ID D07UHS
NDC Product Code 54893-0026; 65035-201
Synonyms Fingolimod Hydrochloride | 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride | FTY-720 | FTY 720 | FTY720 | Gilenya | Gilenia | Fingolimod
Chemical Information
Molecular Formula C19H33NO2
CAS Registry Number 162359-55-9
SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic myeloid leukaemia16.01.07.001; 01.10.07.001--Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Chronic sinusitis22.07.03.018; 11.01.13.0160.002316%Not Available
Circulatory collapse24.06.02.001--Not Available
Claustrophobia19.06.03.0050.001158%Not Available
Clavicle fracture12.04.01.010; 15.08.03.0100.001737%Not Available
Clonus17.02.05.0020.004053%Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.004--Not Available
Clumsiness17.01.02.0050.008685%Not Available
Coagulopathy01.01.02.001--Not Available
Coarctation of the aorta24.04.01.002; 03.07.08.001--Not Available
Cold sweat23.02.03.002; 08.01.03.0240.006948%Not Available
Colitis07.08.01.001--
Colitis ischaemic24.04.08.012; 07.08.01.004--Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Colon cancer16.13.01.001; 07.21.01.0010.002417%Not Available
Colour blindness06.02.09.001; 03.01.01.0010.002316%Not Available
Colour blindness acquired06.02.09.0020.001737%Not Available
Coma17.02.09.001--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Complex partial seizures17.12.02.0030.002895%Not Available
Compression fracture15.08.02.004; 12.04.02.0080.001737%Not Available
Concussion17.11.01.004; 12.01.10.0050.004632%Not Available
Conduction disorder02.03.01.0080.003474%
Confusional state19.13.01.001; 17.02.03.005--
Congenital central nervous system anomaly17.19.01.003; 03.10.02.0040.001158%Not Available
Conjunctival haemorrhage06.07.01.001; 24.07.05.0010.003474%Not Available
Conjunctivitis11.01.06.012; 06.04.01.0020.011580%
Constipation07.02.02.001--
Conversion disorder19.24.01.0010.001158%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 63 Pages